Core Insights - Hims & Hers Health, Inc. launched a new specialty in women's health focusing on affordable treatment plans for women experiencing perimenopause and menopause [1][5] - The launch is expected to enhance Hims & Hers' business and solidify its position in the niche market [2][7] Company Developments - Following the announcement, Hims & Hers' shares declined nearly 4.9% [3] - The company currently has a market capitalization of $11.25 billion and an earnings yield of 1.2%, which is better than the industry's negative yield [4] - Hims & Hers estimates that women spend an average of nine years in poor health, which is 25% more than men, impacting their work and community presence [5] - Approximately 1.3 million women in the U.S. experience menopause annually, but only 30% of OB/GYN residency programs provide formal menopause training [5] - Hims & Hers serves over half a million subscribers and aims to surpass $1 billion in annual revenues by 2026 [5][6] Market Potential - The global menopause market is projected to grow from $17.79 billion in 2024 to $24.35 billion by 2030, with a CAGR of approximately 5.4% [7] - The latest product launch is anticipated to significantly boost Hims & Hers' business due to favorable industry trends [7] Stock Performance - Hims & Hers shares have increased by 117.7% over the past year, outperforming the industry and the S&P 500 [10]